α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)
High Sensitive ELISA Kit for Alpha-1-Acid Glycoprotein (a1AGP)
AGP1; a1-AGP; ORM1; OMD 1; Orosomucoid 1
- 編號(hào)HEA816Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3h
- 檢測范圍1.25-80ng/mL
- 靈敏度最小可檢測劑量小于等于0.40ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2255 ¥ 3222 ¥ 14499 ¥ 27387 ¥ 225540
- 欲了解實(shí)際交易價(jià)格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)(加標(biāo)樣品),重復(fù)測定并計(jì)算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 97-104 | 101 |
EDTA plasma(n=5) | 86-101 | 92 |
heparin plasma(n=5) | 80-95 | 90 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個(gè)樣本使用同一試劑盒重復(fù)測定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 84-98% | 79-90% | 87-94% | 96-103% |
EDTA plasma(n=5) | 83-97% | 98-105% | 97-104% | 87-96% |
heparin plasma(n=5) | 98-105% | 92-101% | 80-104% | 95-105% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測溶液A100µL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA816Hu01 | α1-酸性糖蛋白(a1AGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA816Hu01 | α1-酸性糖蛋白(a1AGP)多克隆抗體 | WB |
PAA816Hu02 | α1-酸性糖蛋白(a1AGP)多克隆抗體 | WB; IHC; ICC; IP; FCM |
LAA816Hu71 | α1-酸性糖蛋白(a1AGP)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAA816Hu24 | α1-酸性糖蛋白(a1AGP)單克隆抗體 | WB; IHC; ICC; IP. |
MAA816Hu21 | α1-酸性糖蛋白(a1AGP)單克隆抗體 | WB; IHC |
MAA816Hu22 | α1-酸性糖蛋白(a1AGP)單克隆抗體 | WB,IHC |
MAA816Hu23 | α1-酸性糖蛋白(a1AGP)單克隆抗體 | WB; IHC; ICC; IP. |
FAA816Hu02 | 抗α1-酸性糖蛋白(a1AGP)單克隆抗體 | Flow cytometry. |
LAA816Hu72 | α1-酸性糖蛋白(a1AGP)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
SEA816Hu | α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
HEA816Hu | α1-酸性糖蛋白(a1AGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA816Hu | α1-酸性糖蛋白(a1AGP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSA816Hu01 | α1-酸性糖蛋白(a1AGP)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSA816Hu01 | α1-酸性糖蛋白(a1AGP)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
J Reprod Dev.? | An Acute-phase Protein as a Regulator of Sperm Survival in the Bovine Oviduct: Alpha 1-acid-glycoprotein Impairs Neutrophil Phagocytosis of Sperm In Vitro [Pubmed:Pmc4219990] |
Molecular Reproduction and Development | Evidence for a novel, local acute-phase response in the bovine oviduct: Progesterone and lipopolysaccharide up-regulate alpha 1-acid-glycoprotein expression in epithelial cells in vitro [Pubmed:25123565] |
BMC Complementary and Alternative Medicine | Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study [Pubmed:25652121] |
PLoS One | Gut Microbial Dysbiosis May Predict Diarrhea and Fatigue in Patients Undergoing Pelvic Cancer Radiotherapy: A Pilot Study [PubMed: 25955845] |
Sci Rep.? | S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine [pmc:PMC4810364] |
Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
Scientific Reports | An autoregressive logistic model to predict the reciprocal effects of oviductal fluid components on in vitro spermophagy by neutrophils in cattle [pubmed:28667317] |
33 | Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes. [pubmed:28927749] |
Brazilian Journal of Otorhinolaryngology | Inflammatory markers in palatine tonsils of children with obstructive sleep apnea syndrome [Pubmed: 30213594] |
BioRxiv | Proteome-wide characterization and biomarker identification of intracranial aneurysm [] |
The FEBS journal | Dramatically changed immune‐related molecules as early diagnostic biomarkers of non‐small cell lung cancer [Pubmed: 31482685] |
PLoS One | Effects of vaccination on acute-phase protein response in broiler chicken [Pubmed: 32191767] |
Indian Journal of Animal Sciences | Peripheral concentrations of metabolic and inflammatory indicators during transition period and their relationship with postpartum clinical endometritis in dairy?… [] |
A New Biomarker Tool for Risk Stratification in ?°De Novo?± Acute Heart Failure (OROME) [] |